HOXB9 and cholangiocarcinoma: HOXB9 was significantly higher in UCEC, bladder urothelial carcinoma, breast invasive carcinoma, cholangiocarcinoma, colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and thyroid carcinoma.